Akebia Therapeutics, Inc. AKBA revenue by segment, product and geography
In its fiscal year ending 2025-12-31, Akebia Therapeutics, Inc. reported revenue across 1 business segments; the largest, Reportable Segment, was $236M, 100.0% of the filed sum (+47.5% against the prior period in the same filing).
Reported segment mix
figures as filed · share of the filed sum · change vs the prior period in the same filing- Reportable Segment$236M100.0%+47.5% yoy
Members sum to the consolidated $236M for this period.
- Reportable Segment$23.5M100.0%-146.6% yoy
Members sum to the consolidated $23.5M for this period.
- Product$227Mshare n/a+49.4% yoy
- Auryxia$182Mshare n/a+19.3% yoy
- Vafseo$45.8Mshare n/ano prior
- License Collaboration And Other Revenue$8.86Mshare n/a+10.8% yoy
member sum exceeds the consolidated figure: this axis carries more than one breakdown, so shares are not computed.
- Reportable Segment$53.5M100.0%-6.6% yoy
Change is against the same quarter a year earlier, as reported in the same 10-Q.
Source: SEC DERA Financial Statement and Notes data sets. Dimensional XBRL facts on the business-segment, product/service and geographic axes; the engine keeps the accession of every figure. Descriptive and educational, not advice.
About these figures
Companies tag segment, product and geographic revenue as dimensional XBRL facts in their 10-K and 10-Q filings. The SEC publishes those facts in its DERA Financial Statement and Notes data sets; TrendNalysis ingests each monthly file and serves the facts exactly as filed, keyed to the accession of the filing. Shares are of the filed sum. Where a filer tags more than one breakdown on one axis, the sum exceeds consolidated revenue and no shares are computed; where the members do not add up to the consolidated figure, the residual is stated rather than hidden. Missing is never zero.
Descriptive and educational; not investment advice. Methodology and data lineage.